[
  {
    "ts": null,
    "headline": "EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer",
    "summary": "Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.",
    "url": "https://finnhub.io/api/news?id=a5f86313bb6bccdd44acd7bc9d15de3a53dee60e8fa4a6bfa6e79563ceae3327",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732813320,
      "headline": "EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer",
      "id": 131694993,
      "image": "https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.",
      "url": "https://finnhub.io/api/news?id=a5f86313bb6bccdd44acd7bc9d15de3a53dee60e8fa4a6bfa6e79563ceae3327"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Down 9.4% Since Last Earnings Report: Can It Rebound?",
    "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=177ec975d1aa00ecfccf08345389b00b9029ba0b1c207cd35261c0330241b6b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732811502,
      "headline": "Pfizer (PFE) Down 9.4% Since Last Earnings Report: Can It Rebound?",
      "id": 131700766,
      "image": "https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=177ec975d1aa00ecfccf08345389b00b9029ba0b1c207cd35261c0330241b6b6"
    }
  },
  {
    "ts": null,
    "headline": "OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study",
    "summary": "Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.",
    "url": "https://finnhub.io/api/news?id=ade4ffa64e07a14377ea40d75e99e0401f3c08c343bc87525c15d559a6f0240f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732807740,
      "headline": "OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study",
      "id": 131689950,
      "image": "https://media.zenfs.com/en/zacks.com/701e76528de32ecfd8ed3df2f647e9a8",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.",
      "url": "https://finnhub.io/api/news?id=ade4ffa64e07a14377ea40d75e99e0401f3c08c343bc87525c15d559a6f0240f"
    }
  },
  {
    "ts": null,
    "headline": "Are Investors Undervaluing Pfizer (PFE) Right Now?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=8a2f6bfd8097ce02c1d0fcc64fd489b7fb8f814fbfce62a6ba0fe455c32671e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732804811,
      "headline": "Are Investors Undervaluing Pfizer (PFE) Right Now?",
      "id": 131688274,
      "image": "https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=8a2f6bfd8097ce02c1d0fcc64fd489b7fb8f814fbfce62a6ba0fe455c32671e1"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock in Trouble?",
    "summary": "One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE).  Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 billion in 2022), for many investors, it's still seen as a stock whose best days may be behind it.  Demand for its COVID vaccine is waning, significantly, and some investors may worry about a potential change in vaccine policy under the incoming Trump administration.",
    "url": "https://finnhub.io/api/news?id=df297b9fffd8d7a11cb43ca4fff9bbbbcc10983b961c8fe4cf1da6493417855b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732792620,
      "headline": "Is Pfizer Stock in Trouble?",
      "id": 131686387,
      "image": "https://g.foolcdn.com/editorial/images/798829/investor-analyzing-a-chart.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE).  Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 billion in 2022), for many investors, it's still seen as a stock whose best days may be behind it.  Demand for its COVID vaccine is waning, significantly, and some investors may worry about a potential change in vaccine policy under the incoming Trump administration.",
      "url": "https://finnhub.io/api/news?id=df297b9fffd8d7a11cb43ca4fff9bbbbcc10983b961c8fe4cf1da6493417855b"
    }
  },
  {
    "ts": null,
    "headline": "Why Pfizer Inc. (PFE) Is One of the Most Undervalued Pot Stocks to Buy?",
    "summary": "We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other most undervalued pot stocks to buy according to analysts. A decade ago, the cannabis industry was in full swing as stock […]",
    "url": "https://finnhub.io/api/news?id=93d87f7eea08d722fb350c9762922053fef1c5ea41ecd436b6d26a72f59aeafd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732790347,
      "headline": "Why Pfizer Inc. (PFE) Is One of the Most Undervalued Pot Stocks to Buy?",
      "id": 131686389,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other most undervalued pot stocks to buy according to analysts. A decade ago, the cannabis industry was in full swing as stock […]",
      "url": "https://finnhub.io/api/news?id=93d87f7eea08d722fb350c9762922053fef1c5ea41ecd436b6d26a72f59aeafd"
    }
  },
  {
    "ts": null,
    "headline": "5 Blue Chips Yielding Over 7% I'm Considering Buying, And So Should You",
    "summary": "I'm seeking 6%-plus yielding blue-chip bargains for my family's portfolio. Learn more about BTI, MO, PFE, LYB, and EPD stocks that are alternatives to Enbridge.",
    "url": "https://finnhub.io/api/news?id=1566553713ef4c4d4f34e980b03b05b6cb3876f08b8b2fbe4c724bc812709308",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732777200,
      "headline": "5 Blue Chips Yielding Over 7% I'm Considering Buying, And So Should You",
      "id": 131683050,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288877316/image_1288877316.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "I'm seeking 6%-plus yielding blue-chip bargains for my family's portfolio. Learn more about BTI, MO, PFE, LYB, and EPD stocks that are alternatives to Enbridge.",
      "url": "https://finnhub.io/api/news?id=1566553713ef4c4d4f34e980b03b05b6cb3876f08b8b2fbe4c724bc812709308"
    }
  }
]